

1 / 4

ADCC in the presence of effector cells (PBMC) of different blood donors and polyvalent immunoglobulins
(Tegeline 500µg/ml).




Fig. 1

ADCC induced by anti-Rhesus D on NK of donors of phenotype CD16 F-F 158




Fig. 2

2 / 4

ADCC induced by anti-Rhesus D on NK of donors of phenotype CD16 V-V 158




Fig. 3

Activation of Jurkat CD16 F-158 by anti-D (T125) expressed in YB2/0 and CHO




Fig. 4

3 / 4

Activation of Jurkat CD16 V-158 by anti-D (T125) expressed in YB2/0 and CHO




Fig. 5

Activation of Jurkat CD16 F-158 by anti-HLA-DR antibodies expressed in CHO and YB2/0.




Fig. 6

4 / 4

Activation of Jurkat CD16 V-158 by anti-HLA-DR antibodies expressed in CHO and YB2/O.




Fig. 7